RELATED: The trial win is key for AbbVie and Roche, as it backs up a conditional AML approval the FDA doled out in late 2018 based on response rates. The agency okayed Venclexta in tandem with ...

AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira.

Intensive chemotherapy improved survival in patients with accelerated and blast phase myeloproliferative neoplasms, with ...

The Venclexta-LDAC combo posted a 25% reduction in the risk of death over solo LDAC and extended patients' lives by a median 7.2 months compared with 4.1 months in the LDAC arm, AbbVie said.

AbbVie’s ABBV stock has risen 11.5% in the past month, mainly due to its beat-and-raise performance in the second quarter.

VENCLEXTA/VENCLYXTO is approved in more than 50 countries, including the U.S. Uses and Important VENCLEXTA® (venetoclax) U.S. Safety Information7 UsesVENCLEXTA is a prescription medicine used: ...

After a median follow-up of 28 months, the combination of Imbruvica plus Venclexta significantly improved progression-free survival compared with chlorambucil plus obinutuzumab. Therefore, Imbruvica ...

Venclexta/Venclyxto is a small molecule intended to bind and inhibit the BCL-2 protein, a protein that often resists therapies. Through blocking BCL-2, researchers intend for cancer cells to be ...

Roche co-markets Venclexta in the US with AbbVie, with the latter selling it on its own elsewhere as Venclyxto, and the drug is a key growth product for both companies.

VENCLEXTA in combination with LDAC did not significantly improve OS versus placebo in combination with LDAC. The HR for OS was 0.75 (95% CI: 0.52, 1.07); p-value 0.114.

For AbbVie, Venclexta brought in revenues of $344 million in 2018, up more than 100% year over year driven by uptake in the second-line plus setting following approval in the United States as well ...

For AbbVie, Venclexta brought in revenues of $344 million in 2018, up more than 100% year over year driven by uptake in the second-line plus setting following approval in the United States as well ...